Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02876302 · ClinicalTrials.gov registry record · Phase 2
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
A Phase 2 study of Inflammatory Breast Cancer (IBC), sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 4
- Study locations
NCT02876302 is a Phase 2 study of Inflammatory Breast Cancer (IBC) that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 23 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT02876302, a Phase 2 study of Inflammatory Breast Cancer (IBC), is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. * Paclitaxel (also called Taxol) * Doxorubicin also called Adriamycin * Cyclophosphamide, also called Cytoxan
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Ruxolitinib
Study Locations (4)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Duke University Medical Center - Durham
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02876302
The ClinicalTrials.gov registry entry for NCT02876302 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inflammatory Breast Cancer (IBC) appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02876302 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02876302 about?
NCT02876302 is a clinical study titled "Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer". This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. * Paclitaxel (also called Taxol) * Doxorubicin also called Adriamycin * Cyclophosphamide, also called Cytoxan
What is the current status of trial NCT02876302?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-01-24. Estimated completion is 2026-04.
What conditions does trial NCT02876302 study?
This clinical trial studies the following conditions: Inflammatory Breast Cancer (IBC).
What interventions are being tested in trial NCT02876302?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT02876302?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02876302 being conducted?
This trial has 4 study locations across Massachusetts, Minnesota, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.